MAU2

Across TCGA pan-cancer cohorts, MAU2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAU2 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MAU2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAU2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

COAD, LAML, and PRAD are the cancer types where MAU2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.226	0.700	<.001	15	view →
LAML	DFS	Median	All	0.111	0.572	.010	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.410	.032	6	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAU2–COAD (DFS)

Open the COAD breakdown →